Effect of adriamycin on BRCA1 and PARP-1 expression in MCF-7 breast cancer cells

被引：0

作者：

Wang, Hui ^{[1
]}

Lu, Changqing ^{[1
]}

Tan, Yan ^{[1
]}

Xie, Jun ^{[1
]}

Jiang, Jingting ^{[2
]}

机构：

[1] Soochow Univ, Affiliated Hosp 3, Dept Pathol, Changzhou 213003, Peoples R China

[2] Soochow Univ, Affiliated Hosp 3, Dept Tumor Biol Treatment, Changzhou 213003, Peoples R China

来源：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2014年 / 7卷 / 09期

基金：

中国国家自然科学基金;

关键词：

MCF-7; adriamycin; BRCA1; PARP-1; DNA-DAMAGE; REPAIR;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To study the effects of adriamycin on the expression of BRCA1 and PARP-1 in BRCA1 wild-type MCF-7 cells. We used Western blotting to detect BRCA1 and PARP-1 levels in MCF-7 cells treated with adriamycin, and used flow cytometry to detect apoptotic MCF-7 cells. Results showed that adriamycin can increase PARP-1 activation in a dose-and time-dependent manner. BRCA1 levels were also increased upon treatment with a high dose of adriamycin, but gradually decreased over time. Treatment of MCF-7 cells with 3-ABA inhibited PARP-1 activity, but had no effect on BRCA1 levels. Compared to adriamycin and 3-ABA treatment alone, the co-treatment can increase the apoptosis of MCF-7 cells. Compared to BRCA1-defective HCC1937 cells, adriamycin combined with 3-ABA can further induce apoptosis of MCF-7 cells (P < 0.05). All of these suggested that adriamycin can affect the PARP-1 activation and the expression of BRCA1. Combined with 3-ABA has an additive effect on the rate of apoptosis observed.

引用

页码：5909 / 5915

页数：7

共 23 条

[11] High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs [J].

Lage, H ;

Aki-Sener, E ;

Yalcin, I .

INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (01) :213-220

[12] BRCA1 Expression Is Epigenetically Repressed in Sporadic Ovarian Cancer Cells by Overexpression of C-Terminal Binding Protein 2 [J].

May, Taymaa ;

Yang, Junzheng ;

Shoni, Melina ;

Liu, Shubai ;

He, Housheng ;

Gali, Reddy ;

Ng, Shu-Kay ;

Crum, Christopher ;

Berkowitz, Ross S. ;

Ng, Shu-Wing .

NEOPLASIA, 2013, 15 (06) :600-+

[13]

Mittal N, 2014, CUTAN OCUL TOXICOL

[14] Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases [J].

Morales, Julio C. ;

Li, Longshan ;

Fattah, Farjana J. ;

Dong, Ying ;

Bey, Erik A. ;

Patel, Melina ;

Geo, Jinming ;

Boothman, David A. .

CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2014, 24 (01) :15-28

[15] Targeting the BRCA1/2 Tumor Suppressors [J].

Rosen, Eliot M. ;

Pishvaian, Michael J. .

CURRENT DRUG TARGETS, 2014, 15 (01) :17-31

[16] BRCA1 Deficiency Exacerbates Estrogen-Induced DNA Damage and Genomic Instability [J].

Savage, Kienan I. ;

Matchett, Kyle B. ;

Barros, Eliana M. ;

Cooper, Kevin M. ;

Irwin, Gareth W. ;

Gorski, Julia J. ;

Orr, Katy S. ;

Vohhodina, Jekaterina ;

Kavanagh, Joy N. ;

Madden, Angelina F. ;

Powell, Alexander ;

Manti, Lorenzo ;

McDade, Simon S. ;

Park, Ben Ho ;

Prise, Kevin M. ;

McIntosh, Stuart A. ;

Salto-Tellez, Manuel ;

Richard, Derek J. ;

Elliott, Christopher T. ;

Harkin, D. Paul .

CANCER RESEARCH, 2014, 74 (10) :2773-2784

[17]

Sinha G, 2014, JNCI-J NATL CANCER I, V106, DOI DOI 10.1093/JNCI/DJT447

[18] Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells [J].

Su, JF ;

Ciftci, K .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2002, 34 (08) :950-957

[19]

Tassone P, 2005, INT J ONCOL, V26, P1257

[20] BRCA I expression modulates chemosensitivity of BRCA I-defective HCC1937 human breast cancer cells [J].

Tassone, P ;

Tagliaferri, P ;

Perricelli, A ;

Blotta, S ;

Quaresima, B ;

Martelli, ML ;

Goel, A ;

Barbieri, V ;

Costanzo, F ;

Boland, CR ;

Venuta, S .

BRITISH JOURNAL OF CANCER, 2003, 88 (08) :1285-1291

← 1 2 3 →